Lifeloc Reports 2025 Full Year Results

March 27, 2026 4:13 PM

Lifeloc Technologies, Inc. (OTC:LCTC), a global leader in the development and manufacturing of breath alcohol testing devices, has announced financial results for the 2025 fiscal year ended December 31, 2025.2025 Financial HighlightsLifeloc Technologies reported revenue growth of 6% to $9.027 million for 2025, compared to net revenue of $8.538 million for 2024. We realized a net loss of ($2.470) million, or ($0.90) per diluted share for the year...

Read more

Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate(R) (tiratricol) for MCT8 Deficiency

March 27, 2026 11:55 AM

Egetis Therapeutics (STO:EGTX) - Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for Emcitate® (tiratricol) for the treatment of MCT8 deficiency. Egetis completed the rolling NDA in January 2026. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act...

Read more

Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

March 27, 2026 9:00 AM

Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target of $10.00.The flash report highlights recent developments related to the Company's non-invasive glucose monitoring technology (Woori IO), including increasing global interest in potential licensing and distribution opportunities.Key Highlights from the Flash Report:Global Licensing Interest in...

Read more

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

March 27, 2026 8:30 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced financial results for the year ended December 31, 2025 and provided a corporate update highlighting its strategic focus on the development of its next-generation enVVe® System. Robert Berman, Chief Executive Officer of enVVeno Medical Corporation, stated, "2025 represented a significant inflection point for the Company. Following the FDA's decision...

Read more

The Nomination Committee's Proposals Regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)

March 27, 2026 6:45 AM

Alligator Bioscience (STO:ATORX) - The Nomination Committee of Alligator Bioscience AB (publ) ("Alligator Bioscience") proposes re-election of Hans-Peter Ostler and Denise Goode as ordinary Board members and election of Anna Törner and Jörg Möller as new ordinary Board members. The Nomination Committee also proposes re-election of Hans-Peter Ostler as Chairman of the Board.The Nomination Committee has consisted of Lars Bergkvist (Chairman),...

Read more

Nature Cell Advances Accelerated Approval and Phase 3 Clinical Trial Strategy for JointStem, Outlines Nasdaq Listing Roadmap

March 26, 2026 1:00 PM

Nature Cell Co., Ltd. (Chairman: Dr. Jeong-Chan Ra), a biopharmaceutical company specializing in adult stem cell therapeutics, has formalized its U.S. regulatory strategy for JointStem, simultaneously presenting a roadmap for FDA Accelerated Approval and NASDAQ listing.Building on its Breakthrough Therapy designation, the company is preparing for an FDA meeting in May 2026 to concretize its accelerated approval strategy and finalize Phase 3...

Read more

BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis

March 26, 2026 10:44 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune‑modulatory antibodies, today announced that it has reached a development milestone under a license agreement related to HMI-115, an anti-prolactin receptor antibody targeting moderate to severe endometriosis-associated pain. The achievement follows the initiation of a Phase 3 clinical trial for HMI‑115 by Hope Medicine (Nanjing) Co. Ltd....

Read more

Alligator Bioscience Publishes Annual Report for 2025

March 26, 2026 10:15 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced that the Annual Report for 2025, as well as the company's Remuneration Report, has been published. Because of environmental and cost reasons, Alligator Bioscience has chosen not to print the annual report.The Annual Report and the Remuneration Report are attached as PDFs and are available on the company's website.For further information, please contact:Søren Bregenholt, CEOE-mail:...

Read more

RMTG Subsidiary Cellgenic Commences Full-Scale Manufacturing at First-of-Its-Kind

March 26, 2026 7:55 AM

Regenerative Medical Technologies Group, Inc. (the "Company") (OTCID:RMTG), a global leader in regenerative medicine solutions, today announced through its Global Stem Cells Group (GSCG) subsidiary that the Cellgenic advanced biologics manufacturing facility in Cancún, Mexico, has officially commenced full operations.The Laboratory - believed to be the first facility in Cancún developed specifically for the external manufacturing and...

Read more

Microbix Announces Annual Meeting Voting Results

March 26, 2026 7:00 AM

Microbix Biosystems Inc. (TSX:MBX)(OTCQB:MBXBF) ("Microbix®" or the Company"), a life sciences innovator, manufacturer, and exporter, announces the voting results from the Annual Meeting of Shareholders of the Company (the "Meeting") which was held on March 25, 2026.At the Meeting, 27.44% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the Meeting. Details of all resolutions...

Read more

Vicore Publishes the Annual Report for 2025

March 26, 2026 3:25 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced the publication of the Annual Report for the financial year 2025.The Annual Report for the financial year 2025 is available on the company's website: https://vicorepharma.com/investors/financial-reports/For further information, please contact:Megan Richards, VP of IR, Communications, and...

Read more

Faron Pharmaceuticals Ltd: Faron Appoints New CTO to Strengthen Late-Stage Development Activities

March 26, 2026 3:20 AM

Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company, announces the appointment of Mr. Heikki Jouttijärvi as the Company's Chief Technical Officer (CTO).Heikki Jouttijärvi brings decades of experience in biopharma manufacturing, supply chain management and commercial operations. Most recently, he has been the SVP of Commercial Business Operations at Adverum Biotechnologies, Inc that was acquired by...

Read more

eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026

March 25, 2026 4:10 PM

Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Tuesday, March 31, 2026 at 5:30 PM Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing these results will be issued prior to the call.CEO of eXoZymes, Michael Heltzen, will lead the call...

Read more

Minutes from Annual General Meeting in FluoGuide A/S

March 25, 2026 1:00 PM

FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company") held its annual general meeting on 25 March 2026.To the shareholders of FluoGuide A/S.The annual general meeting was held Wednesday 25 March 2026 at 3.00 PM (CET) at the Company's premises, Titanhus, Titangade 9-13, meeting room - Herakles, DK-2200 Copenhagen N, Denmark.Notice: Represented at the annual general meeting was share capital of nominal DKK 577,754.60 corresponding to 5,777,546...

Read more

Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update

March 25, 2026 8:20 AM

Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) today provided a strategic and financial update highlighting significant improvements in its financial position since August 31, 2024, following a change in management.Since fiscal year-end 2024, the Company has materially strengthened its balance sheet and capital structure. Convertible debt and other liabilities were reduced from $2,350,637 to $436,864, a...

Read more

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

March 24, 2026 7:00 AM

Actuate Therapeutics, Inc. (NASDAQ:ACTU) is a clinical-stage biopharmaceutical company advancing elraglusib, a first-in-class, highly selective small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β). This multimodal agent targets tumor survival pathways, DNA damage response, NF-κB signaling and the tumor immune microenvironment, offering a new potential treatment across multiple difficult-to-treat cancers including metastatic...

Read more

Notice to Annual General Meeting in BioInvent International AB

March 24, 2026 3:20 AM

BioInvent International (STO:BINV) - The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m. CEST, 29 April 2026 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden.The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Annual General Meeting also by voting in advance by post in accordance...

Read more

OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level

March 23, 2026 8:30 AM

OSR Holdings, Inc. (NASDAQ:OSRH) today announced an updated structure of its previously disclosed binding term sheet dated January 13, 2026 with BCM Europe AG for the global licensing of its lead oncology asset VXM01. The revised structure is designed to improve capital efficiency and shift economic benefits directly to the parent company, OSR Holdings and its shareholders.Under the new framework, OSR Holdings will become a direct counterparty...

Read more

Edison Oncology Completes Target Enrollment in Phase 1/2a Orotecan(TM) Clinical Trial

March 20, 2026 9:00 AM

Edison Oncology Holding Corp. ("Edison Oncology" or the "Company") today announced that it has completed target enrollment in its ongoing Phase 1/2a clinical trial (NCT04337177) evaluating Orotecan™, the Company's proprietary oral formulation of irinotecan designed for at-home administration, in adults and children recurrent or relapsed cancers.Achievement of the enrollment target enables the Company to proceed with the pre-specified statistical...

Read more

RETRANSMISSION: MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank 

March 19, 2026 10:05 AM

MindMaze Therapeutics Holding SA (SIX:MMTX) (the Company), a global leader in brain technology and precision neurotherapeutics, today announced that Baader Bank has initiated equity research coverage on the Company's shares.Baader Bank has initiated coverage with a Buy recommendation and a target price of CHF 1.80 per share. This new coverage complements the existing research coverage provided by Edison Group, which currently values the Company...

Read more